Edition:
United Kingdom

Biogen Inc (BIIB.O)

BIIB.O on Nasdaq

336.42USD
3:37pm BST
Change (% chg)

$-5.99 (-1.75%)
Prev Close
$342.42
Open
$343.00
Day's High
$343.31
Day's Low
$336.25
Volume
337,597
Avg. Vol
1,358,947
52-wk High
$348.84
52-wk Low
$244.28

Chart for

About

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis... (more)

Overall

Beta: 0.72
Market Cap(Mil.): $69,239.67
Shares Outstanding(Mil.): 211.43
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 30.44 16.24
EPS (TTM): -- -- --
ROI: -- 14.17 10.90
ROE: -- 15.52 14.09

BRIEF-Biogen updates on new data on treatment with Spinraza

* Presented new data showing earlier initiation of treatment with Spinraza may improve motor function outcomes in infants with spinal muscular atrophy

05 Oct 2017

BRIEF-Biogen appoints Sanjay Jariwala as SVP

* Biogen appoints Sanjay Jariwala as SVP, worldwide medical Source text for Eikon: Further company coverage:

12 Sep 2017

BRIEF-Ionis earns $40 million Spinraza regulatory milestone payment from Biogen

* Ionis earns $40 million Spinraza regulatory milestone payment from Biogen

30 Aug 2017

Samsung, Biogen version of AbbVie's Humira approved in Europe

A biosimilar version of AbbVie Inc's blockbuster arthritis drug Humira, produced by a joint venture of Biogen Inc and Samsung Biologics, was approved by European Union regulators, the partners said on Thursday.

25 Aug 2017

Samsung, Biogen version of AbbVie's Humira approved in Europe

A biosimilar version of AbbVie Inc's blockbuster arthritis drug Humira, produced by a joint venture of Biogen Inc and Samsung Biologics, was approved by European Union regulators, the partners said on Thursday.

25 Aug 2017

UPDATE 1-Samsung, Biogen version of AbbVie's Humira approved in Europe

Aug 24 A biosimilar version of AbbVie Inc's blockbuster arthritis drug Humira, produced by a joint venture of Biogen Inc and Samsung Biologics , was approved by European Union regulators, the partners said on Thursday.

25 Aug 2017

BRIEF-Imraldi, Biogen's Adalimumab Biosimilar referencing Humira, is approved in EU

* Imraldi(®), Biogen's Adalimumab Biosimilar referencing Humira(®), is approved in European Union

25 Aug 2017

BRIEF-Paulson & Co takes share stake in Apple, dissolves share stake in Sarepta, Biogen

* Ups share stake in T-Mobile US Inc by 46.1 percent to 6.1 million shares - SEC filing

14 Aug 2017

BRIEF-Temasek Holdings takes stake in JPMorgan, Biogen, Celgene

* Temasek Holdings (Private) Ltd takes share stake in JPMorgan Chase & Co of 264,337 shares

14 Aug 2017

BRIEF-Biogen appoints Anabella Villalobos senior vice president, Biotherapeutic & Medicinal Sciences

* Biogen appoints Anabella Villalobos senior vice president, Biotherapeutic & Medicinal Sciences Source text for Eikon: Further company coverage:

31 Jul 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $142.05 +0.01
Pfizer Inc. (PFE.N) $36.11 -0.13
Novartis AG (NOVN.S) CHF84.45 +0.10
Merck & Co., Inc. (MRK.N) $63.73 -0.02
Roche Holding Ltd. (ROG.S) CHF234.40 -4.20
Roche Holding Ltd. (RO.S) CHF236.90 -4.80
Bayer AG (BAYGn.DE) €117.95 -0.75
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €83.81 -0.45
GlaxoSmithKline plc (GSK.L) 1,523.50 -12.50

Earnings vs. Estimates